Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study

被引：29
|
作者：
Maglio, Angelantonio [1 ]
Vitale, Carolina [1 ]
Pelaia, Corrado [2 ]
D'Amato, Maria [3 ]
Ciampo, Luigi [1 ]
Sferra, Eliana [3 ]
Molino, Antonio [3 ]
Pelaia, Giulia [2 ]
Vatrella, Alessandro [1 ]
机构：
[1] Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, I-84100 Salerno, Italy
[2] Magna Graecia Univ Catanzaro, Dept Hlth Sci, I-88100 Catanzaro, Italy
[3] Univ Naples Federico II, Dept Resp Med, I-80100 Naples, Italy
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 03期
关键词：
severe asthma; OCS-dependent asthma; asthma remission; mepolizumab; benralizumab; airway inflammation; anti-IL; 5; SUPER-RESPONDER; BENRALIZUMAB; MEPOLIZUMAB;
D O I：
10.3390/ijms24032455
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Add-on biological therapy has proven to be effective in many patients with severe eosinophilic asthma. In this observational multicenter retrospective study, we report the results obtained with mepolizumab and benralizumab in severe asthmatics treated for 12 months in a real-life setting. In these patients, peripheral eosinophil levels, pulmonary function trends, exacerbation rates, systemic corticosteroid use, and symptom control were evaluated during the observation period, to understand which patients met all the criteria in order to be considered in disease remission. The percentage of remittent patients was 30.12% in the mepolizumab-treated subgroup, while in the benralizumab-treated subgroup, patients in complete disease remission were 40%, after 12 months. The results of this study confirm the efficacy of anti-IL-5 biologic drugs in the treatment of severe eosinophilic asthma in a real-life setting.
引用
收藏
页数：11
相关论文
共 50 条
  • [21] Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register
    Soendergaard, Marianne Baastrup
    Hansen, Susanne
    Bjerrum, Anne-Sofie
    Hilberg, Ole
    Lock-Johansson, Sofie
    Hakansson, Kjell Erik Julius
    Ingebrigtsen, Truls Sylvan
    Johnsen, Claus Rikard
    Rasmussen, Linda Makowska
    von Bulow, Anna
    Assing, Karin Dahl
    Schmid, Johannes Martin
    Ulrik, Charlotte Suppli
    Porsbjerg, Celeste
    ERJ OPEN RESEARCH, 2022, 8 (04)
  • [22] REAL WORD EFFECTIVENESS OF ANTI IL-5/IL-5R THERAPIES IN SEVERE ASTHMA WITH FUNGAL SENSITISATION
    Dhariwal, J.
    Hearn, A.
    Kavanagh, J.
    D'Ancona, G.
    Roxas, C.
    Green, L.
    Thomson, L.
    Fernandes, M.
    Kent, B. D.
    Nanzer, A. M.
    Jackson, D. J.
    THORAX, 2021, 76 : A141 - A142
  • [23] Airway epithelial wound healing is impaired in patients with severe asthma unable to down-titrate anti IL5 biologics
    Soendergaard, Marianne Baastrup
    Andreasson, Louise Munkholm
    Klein, Ditte Kjaergaard
    Porsbjerg, Celeste
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [24] Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
    Rojo-Tolosa, Susana
    Gonzalez-Gutierrez, Maria Victoria
    Jimenez-Galvez, Gonzalo
    Sanchez-Martinez, Jose Antonio
    Pineda-Lancheros, Laura Elena
    Galvez-Navas, Jose Maria
    Jimenez-Morales, Alberto
    Perez-Ramirez, Cristina
    Morales-Garcia, Concepcion
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [25] Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
    Burkill, S.
    Porsbjerg, C. M.
    Bourdin, A.
    Tran, T. N.
    Martin, N.
    Katial, R.
    Barker, P.
    Wechsler, M. E.
    Maspero, J.
    Bosnic-Anticevich, S.
    Chung, L. P.
    Katsoulotos, G.
    Christoff, G. C.
    Popov, T. A.
    Sadatsafavi, M.
    Torres-Duque, C. A.
    Ulrik, C.
    Assing, K. Dahl
    Hansen, S.
    Altraja, A.
    Lehtimaki, L. A.
    Papadopoulos, N. G.
    Kostikas, K.
    Salvi, S.
    Costello, R. W.
    Francesca, P.
    Iwanaga, T.
    Rhee, C. K.
    Al-Ahmad, M.
    Larenas-Linnemann, D.
    Fonseca, J. A.
    Amaral, R.
    Alving, K.
    Al-Lehebi, R.
    De-Llano, L. Perez
    Kirenga, B.
    Tsai, M.
    Mahboub, B.
    Pfeffer, P. E.
    Henley, W.
    Liu, Y.
    Lyu, J.
    Goh, C.
    Uthaman, T.
    Price, D.
    Townend, J.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [26] Real-World Effectiveness of Anti IL-5/IL-5R Therapies in Severe Asthma with Fungal Sensitisation
    Dhariwal, J.
    Kavanagh, J.
    Roxas, C.
    d'Ancona, G.
    Green, L.
    Thomson, L.
    Fernandes, M.
    Payne, V.
    Kent, B. D.
    Nanzer, A.
    Jackson, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [27] Anti-IL-5 treatments in severe eosinophilic asthma: real life datas
    Ozdel Ozturk, Betul
    Bavbek, Sevim
    TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2020, 68 (02): : 148 - 159
  • [28] ANTI-IL-5-RECEPTOR TREATMENT IN SEVERE ASTHMA: REAL LIFE DATA
    Baptista, Mafalda
    Costa-Martins, Sara
    Barata, Juliana
    Rocha, Daniel Pimenta
    Craveiro, Ana Pedro
    Lopes, Ines Vicente
    Valente, Maria Beirao
    Valente, Maria
    CHEST, 2021, 160 (04) : 53A - 53A
  • [29] Changing between anti-IL5 and anti-IL5 receptor treatments. A real-life study
    Bjerrum, Anne Sofie
    Skjold, Tina
    Andersen, Helle
    Pedersen, Lene
    Schmid, Johannes
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [30] A comparison of the impact of anti-IL5/5r therapies in allergic versus non-allergic patients with severe eosinophilic asthma in a real-life setting
    Navarro-Cascales, Tatiana
    Colque-Bayona, Monica
    Fernandez-Concha, Ines
    Laorden, Daniel
    Quirce, Santiago
    Dominguez-Ortega, Javier
    JOURNAL OF ASTHMA, 2025, 62 (02) : 319 - 327
12345